Clinical trials: Advanced Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy Era
This retrospective real-world cohort study will evaluate the efficacy and safety of different radiotherapy target volume extents in patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07879898
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups.
- Trial name
- NCT07559045
- Testing
- Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Gastrointestinal Tract Malignancies
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and…
- Trial name
- EDGE-Gastric (NCT05329766)
- Testing
- Domvanalimab, Quemliclustat, Zimberelimab
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 332 people
- Sponsor
- Arcus Biosciences, Inc.
Gastric Cancer
Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens
The objective of this study is to compare the possible time savings from reduction of nursing and pharmacy time to manage AEGC patients using capecitabine-based regimens versus traditional intravenous chemotherapy in the Hong…
- Trial name
- NCT02063412
- Sponsor
- Vivian Wing Yan Lee
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Esophageal Cancer
Chemoradiotherapy for Advanced Esophageal Cancer
This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with…
- Trial name
- PaRCUS (NCT02297217)
- Testing
- Carboplatin and Taxol (paclitaxel), External Beam Radiation
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- AHS Cancer Control Alberta
Esophageal Squamous Cell Carcinoma
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06446726
- Testing
- Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Oesophago-gastric Cancer
REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients…
- Trial name
- REAL3 (NCT00824785)
- Testing
- epirubicin, oxaliplatin, capecitabine (EOX), EOX + panitumumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Squamous Cell Carcinoma (ESCC)
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy…
- Trial name
- NCT06912074
- Testing
- Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Gastric Cancer
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00040859
- Testing
- capecitabine, oxaliplatin
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT04164069
- Testing
- Bevacizumab, Dasatinib, Fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Anne Noonan
Esophageal Cancer
Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™ with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection.
- Trial name
- NCT00051480
- Testing
- TNFerade
- Where
- 12 sites in United States
- Sponsor
- GenVec
Esophageal Squamous Cell Carcinoma, Efficacy
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity
- Trial name
- NCT06281886
- Testing
- Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Gastric Cancer
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic…
- Conditions
- Esophageal Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06008054
- Testing
- SI-B003, BL-B01D1, PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital